Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss which populations are seen as the most underrepresented in oncology clinical trials.

The California wildfires severely affected patients with cancer, requiring evacuation protocols, community support, and ...

Researchers develop targeted polymersomes loaded with methotrexate for the treatment of gestational choriocarcinoma, ...

JPMorgan raised the firm’s price target on Auna (AUNA) to $13.50 from $13 and keeps an Overweight rating on the shares. The company’s main ...

Lung cancer is a particularly challenging form of cancer. It often strikes unexpectedly and aggressively with little warning, and it can shapeshift in unpredictable ways to evade treatment.

Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceuticals for diabetes, oncology, immunology, neuroscience, and other therapeutic areas worldwide.

The risk of developing liver cancer is increased in people who have cirrhosis, a disease in which healthy liver tissue is ...

TheraBionic is the only FDA-approved therapy indicated in liver cancer patients that fail first-line and second-line therapy, so that's really the place it takes right now in 2025. Patients can ...

Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...